手機版
化工儀器網(wǎng)手機版
化工儀器網(wǎng)小程序
官方微信
公眾號：chem17
掃碼關(guān)注視頻號
資料簡介
matriksbiotek2024年價格表
Matriks Biotek專門生產(chǎn)針對抗體藥的ELISA試劑盒，用于檢測抗體藥的體內(nèi)含量或因用于產(chǎn)生的針對相應(yīng)抗體藥的抗體的體內(nèi)含量。Matriks Biotek®, SHIKARI®和KLONART®為Matriks生物技術(shù)公司注冊的產(chǎn)品商標。其產(chǎn)品達到ISO 13485 & CE IVD標準。
MatriksBiote抗體藥是一類相對新型的生物制劑。檢測抗體藥及其抗體水平在治療和個性化用藥上具有重要意義。大量的臨床和制藥公司都在致力于抗體藥物的濃度水平和療效的研究。
特別告知：為保證產(chǎn)品質(zhì)量與良好性能，所以在購買相應(yīng)產(chǎn)品的同時我司會收取一定量的運輸費用?。?！本次報價有效時間為2024年1月8日---2024年12月14日。
| 貨號 | 品名 | 規(guī)格 | 價格 | 品牌 | 貨期 | 價格來源 |
| ABA-FD-ORE | Abatacept (Orencia®) Free drug | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ABA-QLS-ORE | Abatacept (Orencia®) Antibody screening - Qualitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ABA-QNS-ORE | Abatacept (Orencia®) Antibody screening - Quantitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-FD-HUM | Adalimumab (Humira®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-QLS-HUM | Adalimumab (Humira®) Antibody screening - Qualitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-QNFT-HUM | Adalimumab (Humira®) Antibody screening - Free/Total semiquantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-QNS-HUM | Adalimumab (Humira®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-SPEC-ADA | Adalimumab (Humira®) Free drug / Specific | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| AFL-FD-EYL | Aflibercept (Eylea®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| AFL-FD-SENS-EYL | Aflibercept (Eylea®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| AFL-QLS-EYL | Aflibercept (Eylea®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| AFL-QNS-EYL | Aflibercept (Eylea®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ATE-FD-TEC | Atezolizumab (Tecentriq®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ATE-QLS-TEC | Atezolizumab (Tecentriq®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| BEV-FD-AA | Bevacizumab (Avastin®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| CAN-FD-ILA | Canakinumab (Ilaris®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| CAN-QLS-ILA | Canakinumab (Ilaris®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| CAN-QNS-ILA | Canakinumab (Ilaris®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DAR-FD-DAR | Daratumumab (Darzalex®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DAR-QLS-DAR | Daratumumab (Darzalex®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DEN-QNS-PRO | Denosumab (Prolia®) Antibody screening - Quantitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DUR-FD-IMF | Durvalumab (Imfinzi®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DUR-QLS-IMF | Durvalumab (Imfinzi®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ETA-FD-ENB | Etanercept (Enbrel®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| EVO-FD-REP | Evolocumab (Repatha® ) Free drug | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| EVO-QLS-REP | Evolocumab (Repatha® ) Antibody screening - Qualitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-FD-REMI | Infliximab (Remicade®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-FD-REMS | Infliximab (Remsima®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QLS-REMI | Infliximab (Remicade®) Antibody screening - Qualitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QLS-REMS | Infliximab (Remsima®) Antibody screening - Qualitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QNFT-REMI | Infliximab (Remicade®) Antibody screening - Free/Total semiquantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QNFT-REMS | Infliximab (Remsima®) Antibody screening - Total semiquantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QNS-REMI | Infliximab (Remicade®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QNS-REMS | Infliximab (Remsima®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-SPEC-INF | Infliximab (Remicade®) Free drug / Specific | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| NIV-FD-OPD | Nivolumab (Opdivo®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| PAL-FD-SYN | Palivizumab (Synagis® ) Free drug | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| PAL-QLS-SYN | Palivizumab (Synagis® ) Antibody screening - Qualitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| PAL-QNS-SYN | Palivizumab (Synagis® ) Antibody screening - Quantitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| PEM-FD-KEY | Pembrolizumab (Keytruda®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| RAN-FD-LUC | Ranibizumab (Lucentis®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| RIT-FD-RM | Rituximab (Rituxan®, Mabthera®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| RIT-QLS-RM | Rituximab (Rituxan®, Mabthera®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| RIT-QNS-RM | Rituximab (Rituxan®, Mabthera®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| SEC-FD-VER | Secukinumab (Cosentyx® , Verxant®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| SEC-QLS-VER | Secukinumab (Cosentyx® , Verxant®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| TOC-QNS-ACT | Tocilizumab (Actemra®) Antibody screening - Quantitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| TRA-FD-HH | Trastuzumab (Herceptin®, Herclon®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| UST-QLS-STE | Ustekinumab (Stelara®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| VED-FD-ENT | Vedolizumab (Entyvio®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| VED-QLS-ENT | Vedolizumab (Entyvio®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
（*此為部分產(chǎn)品價格完整價格請下載文件）
關(guān)鍵詞：matriksbiotek、Matriks Biotek®、KLONART®、SHIKARI®、ELISA試劑盒
相關(guān)產(chǎn)品
免責聲明
- 凡本網(wǎng)注明“來源：化工儀器網(wǎng)”的所有作品，均為浙江興旺寶明通網(wǎng)絡(luò)有限公司-化工儀器網(wǎng)合法擁有版權(quán)或有權(quán)使用的作品，未經(jīng)本網(wǎng)授權(quán)不得轉(zhuǎn)載、摘編或利用其他方式使用上述作品。已經(jīng)本網(wǎng)授權(quán)使用作品的，應(yīng)在授權(quán)范圍內(nèi)使用，并注明“來源：化工儀器網(wǎng)”。違反上述聲明者，本網(wǎng)將追究其相關(guān)法律責任。
- 本網(wǎng)轉(zhuǎn)載并注明自其他來源（非化工儀器網(wǎng)）的作品，目的在于傳遞更多信息，并不代表本網(wǎng)贊同其觀點和對其真實性負責，不承擔此類作品侵權(quán)行為的直接責任及連帶責任。其他媒體、網(wǎng)站或個人從本網(wǎng)轉(zhuǎn)載時，必須保留本網(wǎng)注明的作品第一來源，并自負版權(quán)等法律責任。
- 如涉及作品內(nèi)容、版權(quán)等問題，請在作品發(fā)表之日起一周內(nèi)與本網(wǎng)聯(lián)系，否則視為放棄相關(guān)權(quán)利。
采購中心